B. Wonke

发表

Management of pregnancy in a patient with beta thalassaemia major.

A. Butwick, I. Findley, B. Wonke, 2005, International journal of obstetric anesthesia.

Assessment of hepatic iron overload in thalassemic patients by magnetic resonance spectroscopy

G. Radda, G. Kemp, P. Styles, 1994, Hepatology.

siderosis beta-thalassemia major patients with asymptomatic myocardial Randomized controlled trial of deferiprone or deferoxamine in

D. Pennell, M. Tanner, R. Galanello, 2009 .

Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long‐term blood transfusions

D. Pennell, M. Tanner, T. Hamblin, 2007, British journal of haematology.

Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine.

A. Hoffbrand, B. Wonke, M. Aldouri, 1987, Journal of clinical pathology.

Left ventricular diastolic function compared with T2* cardiovascular magnetic resonance for early detection of myocardial iron overload in thalassemia major

D. Pennell, M. Westwood, A. Maceira, 2005, Journal of magnetic resonance imaging : JMRI.

Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance

D. Pennell, L. Anderson, M. Westwood, 2004, British journal of haematology.

Alpha interferon in the treatment of chronic hepatitis C infection in thalassaemia major

K. Ganeshaguru, A. Hoffbrand, G. Dusheiko, 1993, British journal of haematology.

New Approaches to the Management of Hepatitis and Endocrine Disorders in Cooley's Anemia

A. Hoffbrand, P. Telfer, B. Wonke, 1998, Annals of the New York Academy of Sciences.

Serum non‐transferrin‐bound iron in beta‐thalassaemia major patients treated with desferrioxamine and L1

A. Hoffbrand, G. Kontoghiorghes, B. Wonke, 1992, British journal of haematology.

A multidisciplinary approach for improving services in primary care: randomised controlled trial of screening for haemoglobin disorders

M. Modell, S. S. Tai, B. Modell, 1998, BMJ.

Incidence of endocrine complications and clinical disease severity related to genotype analysis and iron overload in patients with β‐thalassaemia

A. Hoffbrand, R. Morris, J. Old, 1997, European journal of haematology.

Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.

A. Hoffbrand, G. Kontoghiorghes, L. Sheppard, 1987, British medical journal.

Endocrine Abnormalities in Thalassemia

A. Hoffbrand, B. Bagni, G. Tolis, 1990, Annals of the New York Academy of Sciences.

The development of diabetes mellitus and chronic liver disease in long term chelated beta thalassaemic patients.

V. De Sanctis, G. D'Ascola, B. Wonke, 1986, Postgraduate medical journal.

A novel δº mutation in cis with Hb Knossos: a study of different genetic interactions in three Egyptian families

A. Hoffbrand, S. Thein, R. Olds, 1991 .

Microcytosis, iron deficiency and thalassaemia in a multi‐ethnic community: a pilot study

B. Modell, B. Wonke, M. Modell, 2007, Scandinavian journal of clinical and laboratory investigation.

Psychosocial and clinical burden of thalassaemia intermedia and its implications for prenatal diagnosis.

D. Skuse, A. Yardumian, J. Porter, 1995, Archives of disease in childhood.

Fertility in β thalassaemia major: a report of 16 pregnancies, preconceptual evaluation and a review of the literature

B. Wonke, C. Jensen, S. Tuck, 1995 .

Terminal Deoxynucleotidyl Transferase Expression in Acute Non‐lymphoid Leukaemia: an Analysis by Immunofluorescence

G. Janossy, G. Pizzolo, K. Ganeshaguru, 1981, British Journal of Haematology.

Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia ☆

D. Pennell, L. Anderson, J. M. Walker, 2003 .

Antibody to hepatitis C virus in multiply transfused patients with thalassaemia major.

A. Hoffbrand, G. Dusheiko, David Brown, 1990, Journal of clinical pathology.

Clinical aspects of transfusional iron overload

V. Sanctis, B. Wonke, 2000 .

Intradermal hepatitis B vaccine in thalassaemia and sickle cell disease.

Q. Mok, D. Jefferies, B. Wonke, 1989, Archives of disease in childhood.

Reversal of desferrioxamine induced auditory neurotoxicity during treatment with Ca-DTPA.

A. Hoffbrand, B. Wonke, M. Aldouri, 1989, Archives of disease in childhood.

Effect of different treatment regimes on linear growth and final height in β‐thalassaemia major

B. Bagni, C. Vullo, V. Sanctis, 1994, Clinical endocrinology.

Sperm concentrations and quality in β‐thalassaemia major

B. Wonke, A. Abdel-Gadir, S. Tuck, 1996 .

5 Results of long-term subcutaneous desferrioxamine therapy

A. Hoffbrand, B. Wonke, 1989 .

Induction of spermatogenesis in thalassaemia.

B. Bagni, V. De Sanctis, C. Vullo, 1988, Fertility and sterility.

Clinical management of -Thalassemia major

B. Wonke, 2001 .

Deferiprone‐associated myelotoxicity

A. Hoffbrand, B. Wonke, F. Al‐Refaie, 1994, European journal of haematology.

Results of long‐term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators

A. Hoffbrand, N. Olivieri, C. Hershko, 1995, British journal of haematology.

Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients.

A. Hoffbrand, B. Wonke, J. Cochrane, 1998, Blood.

Pregnancy management and outcomes in women with thalassaemia major.

A. Yardumian, B. Wonke, S. Tuck, 1998, Journal of pediatric endocrinology & metabolism : JPEM.

Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload

A. Hoffbrand, L. Sheppard, B. Wonke, 1995, British journal of haematology.

4 The management of haemoglobinopathies

S. Davies, B. Wonke, 1991 .

Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia

D. Pennell, L. Anderson, J. M. Walker, 2002, The Lancet.

Cardiac iron deposition is not predicted by conventional markers of iron overload in homozygous beta-thalassaemia.

D. Pennell, D. Firmin, L. Anderson, 2000 .

Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major.

A. Hoffbrand, G. Kontoghiorghes, B. Wonke, 1992, Blood.

Ironstate andhepatic disease inpatients with thalassaemia major, treated withlongterm subcutaneous desferrioxamine

A. Hoffbrand, B. Wonke, M. Aldouri, 2011 .

A novel method of cardiac iron measurement using magnetic resonance T2*imaging in thalassemia: Validation and clinical application

D. Pennell, D. Firmin, L. Anderson, 2000 .

Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major.

A. Hoffbrand, J. Agnew, M. Lalloz, 1998, Journal of pediatric endocrinology & metabolism : JPEM.

High incidence of osteoporosis in thalassaemia major.

A. Hoffbrand, J. Agnew, R. Morris, 1998, Journal of pediatric endocrinology & metabolism : JPEM.

Bone disease in beta-thalassaemia major.

B. Wonke, 1998, British journal of haematology.

Iron chelation therapy

A. Hoffbrand, B. Wonke, A. V. Hoffbrand, 1997, Journal of internal medicine. Supplement.

Unresolved Problems in Optimal Therapy of Pubertal Disorders in Oncological and Bone Marrow Transplanted Patients

A. Hokken-Koelega, E. Di Battista, V. De Sanctis, 2001, Journal of pediatric endocrinology & metabolism : JPEM.

Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients

J. Garson, A. Hoffbrand, P. Grant, 1997, British journal of haematology.

WNG lERMDEFERIPRONE CHElATION TIIERAPY

B. Wonke, V. Hoffbrand, 2002 .

Long term deferiprone chelation therapy.

B. Wonke, V. Hoffbrand, 2002, Advances in experimental medicine and biology.

A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload

A. MacDowell, A. Hoffbrand, B. Wonke, 1996, British journal of haematology.

Antilymphocyte globulin therapy enhances impaired function of natural killer cells and lymphokine activated killer cells in aplastic anaemia

A. Myint, E. Gordon-Smith, B. Wonke, 1990, British journal of haematology.

Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload.

D N Firmin, D J Pennell, D. Pennell, 2001, European heart journal.

Gonadal function in patients with beta thalassaemia major.

B. Bagni, V. De Sanctis, C. Vullo, 1988, Journal of clinical pathology.

Changes in transferrin saturation after treatment with the oral iron chelator deferiprone in patients with iron overload.

A. Hoffbrand, B. Wonke, C. E. de Silva, 1995, Journal of clinical pathology.

Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.

A. Hoffbrand, Y. Aydinok, B. Wonke, 1994, Journal of clinical pathology.

REMISSION INDUCTION WITH ADENOSINE-DEAMINASE INHIBITOR 2'-DEOXYCOFORMYCIN IN THY-LYMPHOBLASTIC LEUKÆMIA

G. Janossy, J. Smyth, K. Ganeshaguru, 1980, The Lancet.

Autosomal dominant transmission of congenital erythroid hypoplastic anemia with radial abnormalities.

J. Hurst, M. Baraitser, B. Wonke, 1991, American journal of medical genetics.

Effect of a thalassaemia trait and enhanced y chain production on disease severity in thalassaemia major and intermedia

P. Gringras, A. Fitches, J. Old, 2004 .

and intermedia . disease severity in beta thalassaemia major enhanced gamma chain production on Effect of alpha thalassaemia trait and

P. Gringras, A. Fitches, J. Old, 2004 .

Effect of alpha thalassaemia trait and enhanced gamma chain production on disease severity in beta thalassaemia major and intermedia.

P. Gringras, A. Fitches, J. Old, 1994, Archives of disease in childhood.

A study of hepatitis B and C prevalence and liver function in multiply transfused thalassemic and their parents.

B. Wonke, S. M. Donohue, T. Williams, 1992, Indian pediatrics.

Impact and future of screening for haemoglobin disorders

B. Modell, B. Wonke, 1998 .

Clinical management of beta-thalassemia major.

B. Wonke, 2001, Seminars in hematology.

Lifetime treatment costs of beta-thalassaemia major.

J. Karnon, A. Ades, J. Brown, 1999, Clinical and laboratory haematology.

Clinical Management of P-Thalassemia Major

B. Wonke, 2001 .

Relationship between the severity of β‐thalassaemia syndromes and the number of alleviating mutations

M. Petrou, J. Old, J. Porter, 1997, European journal of haematology.

Management of Beta Thalasseamia Major

B. Wonke, 1994 .

USE OF BONE-MARROW CULTURE IN PREDICTION OF ACUTE LEUKAEMIC TRANSFORMATION IN PRELEUKAEMIA

A. Hoffbrand, B. Wonke, J. Berney, 1983, The Lancet.

Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.

Mark A Westwood, Dudley J Pennell, D. Pennell, 2006, Blood.

Agranulocytosis in a patient with thalassaemia major during treatment with the oral iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one.

P. Veys, A. Hoffbrand, B. Wonke, 1993, Acta haematologica.

A prospective trial of young red cells in 48 patients with transfusion‐dependent thalassaemia

R. Marcus, E. Huehns, H. Taite, 1985, British journal of haematology.

Hepatic iron concentration combined with long‐term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major

A. Hoffbrand, B. Wonke, S. Holden, 2000, British journal of haematology.

Development of Thalassaemic Iron Overload Cardiomyopathy despite Low Liver Iron Levels and Meticulous Compliance to Desferrioxamine

D. Pennell, L. Anderson, M. Westwood, 2006, Acta Haematologica.

Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia

Mark A Westwood, Dudley J Pennell, David N Firmin, 2003, Journal of magnetic resonance imaging : JMRI.

A single breath‐hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload

D. Pennell, D. Firmin, L. Anderson, 2003, Journal of magnetic resonance imaging : JMRI.

High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation.

A. Hoffbrand, J. Agnew, Andrew J.W. Hilson, 1990, Acta haematologica.

Arthropathy in thalassaemia patients receiving deferiprone

A. Hoffbrand, N. Olivieri, B. Wonke, 1994, The Lancet.

Results of long-term subcutaneous desferrioxamine therapy.

A. Hoffbrand, B. Wonke, 1989, Bailliere's clinical haematology.

Ocular changes in patients undergoing long-term desferrioxamine treatment.

G. Arden, E. Huehns, C. Kennedy, 1984, The British journal of ophthalmology.

desferrioxamine treatment . undergoing long-term Ocular changes in patients

G. Arden, E. Huehns, C. Kennedy, 2022 .

Sexual performance and fertility potential in patients with beta thalassemia major.

A. Hoffbrand, B. Bagni, V. De Sanctis, 1989, Progress in clinical and biological research.

No Difference in Pubertal Growth and Final Height between Treated Hypogonadal and Non-Hypogonadal Thalassemic Patients

V. De Sanctis, N. Skordis, B. Wonke, 2004, Hormone Research in Paediatrics.

Prediction of consanguinity using human DNA fingerprints.

S. Thein, B. Wonke, R. A. Wells, 1988, Journal of medical genetics.

Recombinant alpha 2B interferon (IFN) in the treatment of chronic hepatitis C disease in thalassaemia major (TM).

A. Hoffbrand, P. Scheuer, G. Dusheiko, 1993, Bone marrow transplantation.

Endocrine complications in thalassaemia major.

B. Bagni, V. De Sanctis, A. D. Di Palma, 1989, Progress in clinical and biological research.

The interpretation of platelet kinetic studies for the identification of sites of abnormal platelet destruction

S. Lewis, A. Peters, B. Wonke, 1984, British journal of haematology.

Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron

D. Pennell, L. Anderson, M. Westwood, 2007, Journal of magnetic resonance imaging : JMRI.

Interaction of hemoglobin E and pyrimidine 5' nucleotidase deficiency.

H. Simmonds, J. Clegg, D. Weatherall, 1996, Blood.

Myocardial tissue characterization and the role of chronic anemia in sickle cell cardiomyopathy

D. Pennell, L. Anderson, M. Tanner, 2007, Journal of magnetic resonance imaging : JMRI.

Combined oral and parenteral iron chelation in beta thalassaemia major.

B. Wonke, K. Pyar, K. Balveer, 2000, The Medical journal of Malaysia.

Moderate reduction of beta-globin gene transcript by a novel mutation in the 5' untranslated region: a study of its interaction with other genotypes in two families.

S. Thein, C. Fisher, J. Rochette, 1996, Blood.

Normalized Left Ventricular Volumes and Function in Thalassemia Major Patients with Normal Myocardial Iron.

D. Pennell, L. Anderson, M. Westwood, 2005 .

Fertility in beta thalassaemia major: a report of 16 pregnancies, preconceptual evaluation and a review of the literature.

B. Wonke, S. Tuck, C. Jensen, 1995, British journal of obstetrics and gynaecology.

Hypothalamic-Pituitary-Gonadal Axis in Thalassemic Patients With Secondary Amenorrhea

B. Bagni, V. De Sanctis, C. Vullo, 1988, Obstetrics and gynecology.

Iron chelation with oral deferiprone in patients with thalassemia.

A. Hoffbrand, P. Telfer, B. Wonke, 1998, The New England journal of medicine.

SECONDARY ERYTHROCYTOSIS AND SARCOIDOSIS

B. Wonke, D. Bowen, P. M. Cotes, 1989, British journal of haematology.

The effect of deferiprone (L1) and desferrioxamine on myelopoiesis using a liquid culture system

A. Hoffbrand, B. Wonke, S. Wilkes, 1994, British journal of haematology.

Pharmacokinetics of sex steroids in patients with beta thalassaemia major.

B. Bagni, V. De Sanctis, C. Vullo, 1993, Journal of clinical pathology.

Glucose Intolerance and Diabetes in Thalassaemia major

B. Wonke, J. Hanslip, 1995 .

Cardiac complications in homozygous beta-thalassemia.

A. Hoffbrand, B. Wonke, M. Aldouri, 1989, Progress in clinical and biological research.

Gynaecomastia during successful augmentation of spermatogenesis with gonadotrophin therapy in a man with beta thalassaemia major

B. Wonke, S. Tuck, C. Jensen, 1996 .

Semen parameters in patients with homozygous β-thalassemia

C. Vullo, D. Mazzotta, B. Wonke, 1989 .

Combined therapy with deferiprone and desferrioxamine

Wright, A. Hoffbrand, Hoffbrand, 1998, British journal of haematology.

The management of haemoglobinopathies.

S. Davies, B. Wonke, 2002, Bailliere's clinical haematology.

Management of Puberty for Optimal Auxological Results in β-Thalassaemia Major

V. De Sanctis, L. Cavallo, N. Skordis, 2001, Journal of pediatric endocrinology & metabolism : JPEM.

High prevalence of low bone mass in thalassaemia major

Prescott, Jensen, A. Hoffbrand, 1998, British journal of haematology.